KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cme (CME) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Cme (CME) over the last 17 years, with Q3 2025 value amounting to $725.7 million.

  • Cme's Other Non-Current Liabilities fell 567.98% to $725.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $725.7 million, marking a year-over-year decrease of 567.98%. This contributed to the annual value of $721.2 million for FY2024, which is 964.67% down from last year.
  • Per Cme's latest filing, its Other Non-Current Liabilities stood at $725.7 million for Q3 2025, which was down 567.98% from $720.2 million recorded in Q2 2025.
  • In the past 5 years, Cme's Other Non-Current Liabilities ranged from a high of $1.1 billion in Q1 2021 and a low of $720.2 million during Q2 2025
  • For the 5-year period, Cme's Other Non-Current Liabilities averaged around $838.9 million, with its median value being $825.8 million (2023).
  • Per our database at Business Quant, Cme's Other Non-Current Liabilities plummeted by 1754.67% in 2022 and then crashed by 311.49% in 2023.
  • Over the past 5 years, Cme's Other Non-Current Liabilities (Quarter) stood at $896.5 million in 2021, then dropped by 7.86% to $826.0 million in 2022, then fell by 3.37% to $798.2 million in 2023, then dropped by 9.65% to $721.2 million in 2024, then increased by 0.62% to $725.7 million in 2025.
  • Its Other Non-Current Liabilities stands at $725.7 million for Q3 2025, versus $720.2 million for Q2 2025 and $721.2 million for Q1 2025.